MiNK Therapeutics, Inc.

NasdaqCM:INKT Stock Report

Market Cap: US$60.8m

MiNK Therapeutics Management

Management criteria checks 1/4

MiNK Therapeutics' CEO is Jen Buell, appointed in Feb 2021, has a tenure of 5.25 years. total yearly compensation is $2.09M, comprised of 21.5% salary and 78.5% bonuses, including company stock and options. directly owns 1.16% of the company’s shares, worth $706.89K. The average tenure of the management team and the board of directors is 0.4 years and 5.3 years respectively.

Key information

Jen Buell

Chief executive officer

US$2.1m

Total compensation

CEO salary percentage21.46%
CEO tenure5.3yrs
CEO ownership1.2%
Management average tenureless than a year
Board average tenure5.3yrs

Recent management updates

Recent updates

New Narrative • Mar 05

Off The Shelf Cell Therapies Will Reshape Immunotherapy And Support A Long Term Opportunity

Catalysts About MiNK Therapeutics MiNK Therapeutics focuses on allogeneic invariant natural killer T cell therapies aimed at restoring immune balance in cancer, pulmonary disease and transplant settings. What are the underlying business or industry changes driving this perspective?
Analysis Article • Mar 05

MiNK Therapeutics, Inc.'s (NASDAQ:INKT) Intrinsic Value Is Potentially 18% Below Its Share Price

Key Insights The projected fair value for MiNK Therapeutics is US$6.68 based on 2 Stage Free Cash Flow to Equity MiNK...
Analysis Article • Oct 26

MiNK Therapeutics (NASDAQ:INKT) Will Have To Spend Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Jun 28

Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Mar 18

Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 16

MiNK Therapeutics GAAP EPS of -$0.18

MiNK Therapeutics press release (NASDAQ:INKT): Q2 GAAP EPS of -$0.18. Based on the Company’s current plans and projections, MiNK believes its cash and cash equivalents balance as of June 30, 2022 of $29.8M will be sufficient to satisfy its liquidity requirements for more than one year from when these financial statements were issued.
Seeking Alpha • Aug 09

MiNK Therapeutics GAAP EPS of -$0.18

MiNK Therapeutics press release (NASDAQ:INKT): Q2 GAAP EPS of -$0.18. The company ended the second quarter 2022 with a cash balance of $29.8 million as compared to $38.9 million at December 31, 2021.
Seeking Alpha • Jun 23

MiNK Therapeutics A Bargain For Potential Cell Therapies

iNKT cells have unique properties that could be therapeutic. MiNK Therapeutics has shown it can both manufacture and engineer iNKT cells. Preliminary data expected before year-end could push the stock price substantially higher.
Analysis Article • May 05

We're Hopeful That MiNK Therapeutics (NASDAQ:INKT) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Compensation Analysis

How has Jen Buell's remuneration changed compared to MiNK Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$12m

Dec 31 2025US$2mUS$448k

-US$12m

Sep 30 2025n/an/a

-US$12m

Jun 30 2025n/an/a

-US$11m

Mar 31 2025n/an/a

-US$10m

Dec 31 2024US$1mUS$448k

-US$11m

Sep 30 2024n/an/a

-US$14m

Jun 30 2024n/an/a

-US$17m

Mar 31 2024n/an/a

-US$21m

Dec 31 2023US$3mUS$451k

-US$22m

Sep 30 2023n/an/a

-US$25m

Jun 30 2023n/an/a

-US$26m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$4mUS$424k

-US$28m

Sep 30 2022n/an/a

-US$26m

Jun 30 2022n/an/a

-US$34m

Mar 31 2022n/an/a

-US$34m

Dec 31 2021US$3mUS$233k

-US$30m

Sep 30 2021n/an/a

-US$26m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021n/an/a

-US$16m

Dec 31 2020US$917n/a

-US$16m

Compensation vs Market: Jen's total compensation ($USD2.09M) is above average for companies of similar size in the US market ($USD631.70K).

Compensation vs Earnings: Jen's compensation has increased whilst the company is unprofitable.

CEO

Jen Buell (50 yo)

5.3yrs
Tenure
US$2,087,881
Compensation

Dr. Jennifer S. Buell, also known as Jen, Ph.D. is a Director at Agenus Inc since June 11, 2024. She had been Independent Director at Protagenic Therapeutics, Inc. since July 18, 2020. She is a Co-Founder...

Leadership Team

NamePositionTenureCompensationOwnership
Garo Armen
Executive Chairman8.8yrsno data3.47%
$ 2.1m
Jennifer Buell
Co-Founder5.3yrsUS$2.09m1.16%
$ 706.9k
Melissa Orilall
Principal Financial Officerless than a yearno data0.0045%
$ 2.7k
Austin Charette
Principal Accounting Officerless than a yearno data0.00080%
$ 486.2
Terese Hammond
Head of Inflammatory & Pulmonary Diseasesless than a yearno datano data
0.4yrs
Average Tenure
43yo
Average Age

Experienced Management: INKT's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Garo Armen
Executive Chairman8.8yrsno data3.47%
$ 2.1m
Jennifer Buell
Co-Founder5.3yrsUS$2.09m1.16%
$ 706.9k
Robert Stein
Member of the Scientific Advisory Boardno datano datano data
Ulf Wiinberg
Independent Director8.8yrsUS$147.86k0.94%
$ 571.0k
Manuel Hidalgo Medina
Member of the Scientific Advisory Boardno datano datano data
Brian Corvese
Independent Director8.8yrsUS$163.36k0.97%
$ 591.0k
Barbara Ryan
Independent Director4.7yrsUS$162.86k0.41%
$ 249.0k
Mark Exley
Member of the Scientific Advisory Boardno datano datano data
Marcus van Dijk
Scientific Advisory Board Member & Strategic Consultant1.5yrsUS$402.48k0.093%
$ 56.6k
Jenny Gumperz
Member of the Scientific Advisory Boardno datano datano data
Peter Behner
Independent Director5.1yrsUS$156.86k0.37%
$ 227.5k
Lydia Lynch
Member of the Scientific Advisory Boardno datano datano data
5.3yrs
Average Tenure
65yo
Average Age

Experienced Board: INKT's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/31 02:06
End of Day Share Price 2026/05/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MiNK Therapeutics, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Kalpit PatelB. Riley Securities, Inc.
Maneka MirchandaneyEvercore ISI